NCT01476527

Brief Summary

Bipolar Disorder (BD) is among the most comon and challenging conditions in psychiatry. Although episodes of mania and hypomania define the different types of the disorder, the clinical picture is one dominated by depressed mood and agitation. The mainstay of BD treatment has thus far been pharmacologic, but many patients remain severely disabled by their condition, despite the best available medical treatment. The successful use of deep brain stimulation (DBS) in movement disorders, and its promising results in major depressive disorder (MDD), has led researchers to consider its use in highly selected refractory cases of BD. Evidence form the imaging and circuitry literature suggests that similar underlying dyfunctional anatomic structures subserve both MDD and BD, indicating that modulation of key structures, can lead to an amelioration of symptoms and mood stabilization. Here, we propose a phase I clinical trial to evaluate the safety of DBS in BD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2011

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

November 15, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 22, 2011

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

October 30, 2019

Status Verified

October 1, 2019

Enrollment Period

3.1 years

First QC Date

November 15, 2011

Last Update Submit

October 28, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Hamilton Rating Scale for Depression

    Hamilton Depression Rating Scale (HAMD), Montgomery-Åsberg Depression Rating Scale (MADRS)

    Change from baseline in depression scores at 3 months, 6 months and 12 months

Secondary Outcomes (2)

  • Young Mania Rating Scale

    Change from baseline in manic, hypomanic scores at 3 months, 6 months and 12 months

  • Questionnaires-Quality of Life

    Change from baseline in quality of life scores at 3 months, 6 months and 12 months

Study Arms (1)

Deep Brain Stimulation

EXPERIMENTAL

Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone

Procedure: Deep Brain Stimulation

Interventions

Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone

Deep Brain Stimulation

Eligibility Criteria

Age30 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Male or Female patients between the age of 30-60
  • DSM IV-TR diagnosis of Bipolar Disorder I or II
  • Diagnosis for \>12 months with a HRSD-17 score of at least 20
  • Failure of medical therapy, defined as follows:
  • a. Failure of a minimum of two (2) first line as well as two (2) second line treatments for bipolar mania and depression
  • No neurological disease
  • No other active Axis I or Axis II co-morbidity that is the focus of clinical attention, as defined by the Mini International Neuropsychiatric Interview (MINI)
  • No substance abuse or substance use disorder for minimum of three months prior to study
  • Able to give informed consent
  • Able to comply with all testing and follow-up visit requirements defined by the Study Protocol
  • Mini mental status examination (MMSE) score \>25
  • Pre-menopausal women must agree to use acceptable methods of birth control (radiation risk of PET)

You may not qualify if:

  • History of psychosis, or psychotic episodes
  • Alcohol or substance dependence or abuse within 6 months, excluding nicotine or caffeine.
  • Current suicidal ideation, plan or intent for self-harm.
  • A suicide attempt in the past 1 year
  • Major medical illness, cardiac pacemaker/defibrillator, and other implanted stimulator
  • Likely to relocate or move to a location distant from the study site within one year of enrollment
  • Any contraindication to MRI or PET scanning

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto Western Hospital

Toronto, Ontario, M5T 2S8, Canada

Location

MeSH Terms

Conditions

Bipolar Disorder

Interventions

Deep Brain Stimulation

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsSurgical Procedures, Operative

Study Officials

  • Andres M Lozano, MD PhD

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR
  • Roger McIntyre, MD

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Neurosurgeon, Professor of Surgery

Study Record Dates

First Submitted

November 15, 2011

First Posted

November 22, 2011

Study Start

May 1, 2011

Primary Completion

June 1, 2014

Study Completion

June 1, 2014

Last Updated

October 30, 2019

Record last verified: 2019-10

Locations